Aarti Drugs Reports 8% YoY Revenue Growth in Q3 FY26, Up 49% PAT YoY in 9M FY26

Aarti Drugs Limited, a Mumbai-based pharmaceutical company, announced its audited financial results for the quarter and nine months ended December 31, 2025. The company reported an 8% YoY growth in total revenue for Q3 FY26 and a 9% YoY increase in EBITDA for 9M FY26. The PAT stood at Rs. 139.7 crore, up 49% YoY for 9M FY26. The standalone business contributed 88% to the consolidated revenue, with 63% coming from the domestic market and 37% from exports. The API business saw a decline in revenue for Q3 FY26, but the formulation segment grew by 58% YoY. The company is focusing on operational efficiency, margin improvement, and capacity ramp-up.